Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity. The company is focusing on funding its capex internally through internal accruals and existing cash balances. The average interest rate on existing debt is around 9%, and efforts are ongoing to optimize it. Debt reduction is underway but not accelerated, as cash surplus is being allocated primarily to fund project capex. Total debt as of June 30, 2023, stands at INR137 million with a very healthy debt-to-equity ratio of 0.05x. Capex for the full year is projected at INR900 million (including INR600 million pr

Any current/future capex/capital investment/strategic investment?

Vimta Labs is undertaking a significant capex plan focused on Life Sciences facility, expected to be completed by end of 2023, aimed at enhancing pharma division capacity which is currently constrained. Estimated capex for FY 2024 is around INR 90 crores, including approximately INR 60 crores for building construction on existing land and INR 30 crores for equipment replacement, upgradation, and new technology investments. Capex is phased, with additional space almost double the current facility, to be available from Q4 2023; equipment and validation to follow incrementally. New business verti

Future growth expectations in sales/revenue/volumes?

Vimta Labs aims to achieve INR 500 crores revenue target in FY 25-26, with efforts to step up towards INR 1,000 crores thereafter. Growth is expected to be driven primarily by the pharma segment, supported by expansions focusing on clinical and preclinical research services. Food testing growth is anticipated to recover post temporary disruption due to cyclone effects, expected to improve from late Q2 onward. Environment and electronics testing businesses will also contribute to growth, though they form a smaller revenue portion. Despite some capacity constraints currently, these will be addre

Future growth expectations in earnings/operating earnings/profits/EPS?

Vimta Labs aims to achieve INR 500 crores revenue by FY 25-26, targeting a 15%-18% growth rate in coming years. The company expects a 200 basis points (2%) improvement in EBITDA margins as they scale towards INR 500 crores revenue. Margin increases are considered a likely scenario with high possibility, not just a best-case. Growth drivers include pharma, food (noting temporary setbacks), environment, and electronics testing (EMI/EMC). Capacity constraints exist currently, but additional capacity will be operational by Q4 FY24 to support stronger growth post-2023. Subsidiaries like E

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide specific details on the current or expected order book or pending orders for Vimta Labs Limited. There is mention of a strong demand environment, especially in pharma, diagnostics, and electronics testing, indicating a robust pipeline. Capacity constraints are noted, particularly in some services, but expansions are underway with new capacities expected by Q4 FY '24. The management is confident about achieving their revenue target of INR 500 crores driven mainly by pharma and food segments. It is implied that projects they are bidding on or discussing with custo

Vimta Labs LtdQ1 FY24Healthcare Services

Vimta Labs Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹584P/E: 33.1Market Cap: ₹2.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Vimta Labs aims to achieve INR 500 crores revenue target in FY 25-26, with efforts to step up towards INR 1,000 crores thereafter.
Growth is expected to be driven primarily by the pharma segment, supported by expansions focusing on clinical and preclinical research services.
Food testing growth is anticipated to recover post temporary disruption due to cyclone effects, expected to improve from late Q2 onward.
Environment and electronics testing businesses will also contribute to growth, though they form a smaller revenue portion.
Despite some capacity constraints currently, these will be addressed with new capacities operational by Q4 FY24.
The company targets double-digit growth overall; Q1 was weak, but Q2-Q4 should see stronger growth.
Export share (~25-30%) is expected to increase, with export business having better margin profiles.
EBITDA margins targeted to improve by at least 200 basis points with scaling up.

Margin guidance

Category 2

Vimta Labs aims to achieve INR 500 crores revenue by FY 25-26, targeting a 15%-18% growth rate in coming years.
The company expects a 200 basis points (2%) improvement in EBITDA margins as they scale towards INR 500 crores revenue.
Margin increases are considered a likely scenario with high possibility, not just a best-case.
Growth drivers include pharma, food (noting temporary setbacks), environment, and electronics testing (EMI/EMC).
Capacity constraints exist currently, but additional capacity will be operational by Q4 FY24 to support stronger growth post-2023.
Subsidiaries like EMTAC and new business verticals (EMI/EMC, diagnostics) are expected to mature over a few years and contribute significantly in the long term.
Profits after tax showed slight growth (1.3% Y-o-Y in Q1 FY24), with confidence in sustaining growth through enhanced capacity and expanding markets.

See what Vimta Labs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned new fundraising through debt or equity.
The company is focusing on funding its capex internally through internal accruals and existing cash balances.
The average interest rate on existing debt is around 9%, and efforts are ongoing to optimize it.
Debt reduction is underway but not accelerated, as cash surplus is being allocated primarily to fund project capex.
Total debt as of June 30, 2023, stands at INR137 million with a very healthy debt-to-equity ratio of 0.05x.
Capex for the full year is projected at INR900 million (including INR600 million project capex), to be funded internally without additional external financing.

Order book

The transcript does not provide specific details on the current or expected order book or pending orders for Vimta Labs Limited.
There is mention of a strong demand environment, especially in pharma, diagnostics, and electronics testing, indicating a robust pipeline.
Capacity constraints are noted, particularly in some services, but expansions are underway with new capacities expected by Q4 FY '24.
The management is confident about achieving their revenue target of INR 500 crores driven mainly by pharma and food segments.
It is implied that projects they are bidding on or discussing with customers are expected to convert into revenues once capacities increase next year.
No exact figures or quantified order book details were disclosed during the call.

See what Vimta Labs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Vimta Labs is undertaking a significant capex plan focused on Life Sciences facility, expected to be completed by end of 2023, aimed at enhancing pharma division capacity which is currently constrained.
Estimated capex for FY 2024 is around INR 90 crores, including approximately INR 60 crores for building construction on existing land and INR 30 crores for equipment replacement, upgradation, and new technology investments.
Capex is phased, with additional space almost double the current facility, to be available from Q4 2023; equipment and validation to follow incrementally.
New business verticals like EMI/EMC testing are being developed with INR 40 crores investment, expected to take a few years to mature.
No plans to set up additional food labs in the short term.
Capex-to-sales ratio typically ranges from 1 to 1.1 times; funding largely from internal accruals and existing cash reserves.
Strategic approach involves investing ahead of market demand to establish leadership before competitors enter.

Track Vimta Labs Ltd — get its next earnings analysis in your feed

How does Vimta Labs Ltd rank vs peers in Healthcare Services?

Pro feature

ThisVimta Labs Ltd

Rev 3Mar 2

See where Vimta Labs Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Vimta Labs Ltd rank in Healthcare Services?

Compare Vimta Labs Ltd against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Vimta Labs Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
3B Blackbio DX Ltd (Q4 FY24)
41% increase). Key concall takeaways from 3B Blackbio DX Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →